FDA panel: Merck's insomnia drug effective, safe at low doses
WASHINGTON May 22 (Reuters) - Merck & Co's experimental insomnia drug is safe and effective at the lower of two doses studied but not at the higher, a panel of medical experts said on Wednesday.
The panel, which advises the U.S. Food and Drug Administration on matters related to central nervous system disorders, voted 13-3, with one abstention, that the drug, suvorexant, is safe for elderly patients at 15 milligrams a day, and is safe for non-elderly adults at 20 milligrams.
The panel voted 8-7, with two abstentions, that the drug is not safe when given to elderly patients at 30 milligrams or non-elderly adults at 40 milligrams.
- Air strike kills 15 civilians in Yemen by mistake: officials
- North Korea executes leader's powerful uncle in rare public purge |
- Insight: In Yemen, al Qaeda gains sympathy amid U.S. drone strikes
- Storm to cloak Midwest to Northeast in snow, freezing rain
- Twitter backtracks on block feature after users revolt |